Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed SCLC who presented with Limited Stage (LS) at diagnosis. * Measurable disease at the time of initial therapy * Appropriate treatment for LS-SCLC including radiotherapy and chemotherapy. * Responsive disease to standard chemoradiation therapy as defined by RECIST * Patients with CR after chemoradiation therapy are strongly recommended to be treated with prophylactic cranial irradiation * CBC with an absolute neutrophil count (ANC) \>/= 1,000/uL, hemoglobin \>/= 8.0 g/DL and platelet count \>/= 75,000/uL. * Normal prothrombin time (PT) and partial thromboplastin time (aPTT), unless on monitored anticoagulation therapy for medical conditions not excluded in the trial. * Liver enzymes: total bilirubin less than or equal to 2mg/dL; AST and ALT less than 1.5X the upper limit of normal. * Creatinine clearance of \>/= 60 mL/min * Pulmonary: DLCO greater than 50% * Cardiac: left ventricular ejection fraction greater than 45% Exclusion Criteria: * Patient with stable (SD) or progressive disease (PD) after 4 cycles of standard cisplatin and etoposide and concurrent chest irradiation * Pregnant or lactating woman * HIV infection confirmed by NAT * Common variable immunodeficiency * Active CNS malignancy * Active bacterial, fungal or viral infection * Unfavorable psychosocial evaluation or history of poor compliance to prescribed medical care * Prior history of autologous or allogeneic hematopoietic cell transplantation * Presence of protocol specific comorbid conditions